TLDR
- INVO Fertility (IVF) stock surged nearly 145% on Monday after releasing its Q2 2026 earnings report.
- The company posted diluted EPS of $0.35, beating the analyst estimate of -$0.70 by $1.05.
- Revenue came in at $2.17M-$2.18M, slightly missing the $2.4M consensus estimate.
- Growth was driven by a full-quarter contribution from Family Beginnings and the acquisition of a Birmingham, Alabama clinic.
- AI analyst Spark rates IVF stock Neutral with a $0.94 price target, citing ongoing cash burn.
INVO Fertility (IVF) stock exploded 145% on Monday after the company dropped its Q2 2026 earnings report, catching Wall Street off guard with a massive EPS beat.
The stock closed at $0.97 before the move. It had been down 74% year-to-date and 98% over the past 12 months, so Monday’s jump came from a very low base.
The company reported diluted EPS of $0.35 for Q2 2026. That beat the analyst estimate of -$0.70 by $1.05. A year ago, the adjusted EPS was -$364.23.
🚨 $IVF (INVO Fertility) Q2 2026 Results
Revenue up 17%…
clinic growth + acquisition drive, net income turns positive on one-time gain 🚀👶📊 KEY METRICS (Q2 2026)
🔹 Total Revenue: $2.18M (+17% YoY from $1.86M) 🟢
🔹 Clinic Revenue: $2.17M (+18% YoY) 🟢
🔹…— Emmanuel – Big Tech & AI Investor (@EmmanuelInvest) August 17, 2026
Revenue for the quarter came in at $2.17M to $2.18M. That missed the consensus estimate of $2.4M but was up 17% from $1.86M in the same quarter last year.
The trading volume told its own story. More than 55 million IVF shares changed hands on Monday. The company’s three-month average daily volume was around 51,000 shares, making Monday’s activity more than 1,000 times the norm.
What Drove the Q2 Results
CEO Steve Shum pointed to a few key drivers. The biggest was the first full-quarter contribution from Family Beginnings, an Indiana-based fertility clinic.
INVO also completed the acquisition of the remaining stake in its Birmingham, Alabama fertility clinic during the quarter.
The company’s clinic platform generated approximately $333,000 in Adjusted EBITDA before corporate and public company expenses in Q2. For fiscal 2025, that figure was $0.95 million.
INVO also highlighted clinical activity, including five poster abstracts presented at the 2026 Midwest Reproductive Symposium International.
The company said it continues to pursue acquisitions of additional profitable fertility clinics to grow its network.
Wall Street View
INVO Fertility does not have traditional analyst coverage. TipRanks’ AI analyst Spark, which uses the OpenAI 5.2 model, rates IVF stock as Neutral with a price target of $0.94.
Spark flagged “weak financial performance,” including “large losses and ongoing cash burn” as the basis for that stance.
InvestingPro gives INVO Fertility a Financial Health score of “fair performance.”
The company had seen both positive and negative EPS revisions in the 90 days leading up to this report.
Despite Monday’s rally, IVF remains down 38% over the past three months and 98% over the past 12 months.
The Q2 results mark the first time in recent history the company posted positive EPS, a turnaround from the -$364.23 adjusted EPS reported in Q2 2025.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
